Immix Biopharma’s lead asset, IMX-110, is being investigated in a Phase Ib/IIa study for the treatment of soft tissue sarcoma and a Phase Ib trial in advanced solid tumors in combination with tislelizumab. Its preclinical pipeline is based on tissue-specific therapeutics (TSTx) technology.
CAR-T cell therapies have the potential to provide effective treatments for challenging diseases. However, current available options are not considered outpatient treatments due to the risk of serious side effects. If NXC-201 continues to demonstrate a desirable efficacy and safety profile, it could become the first outpatient CAR-T cell therapy.
Healthcare |
Update
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
Flash note
Dr Ilya Rachman
CEO
Gabriel Morris
CFO
Forecast net debt (US$m)
15.1
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (2.2) | (25.2) | (9.5) |
Relative | (5.3) | (28.9) | (28.5) |
52 week high/low | US$7.3/US$1.6 |
Immix Biopharma is focused on the development of novel CAR-T cell therapies and TSTx. Lead CAR-T asset (NXC-201) is being assessed in the Phase Ib/IIa NEXICART-1 trial for multiple myeloma and AL amyloidosis (ALA). Rolling data readouts to date have demonstrated high response rates and a desirable safety profile. The NEXICART-2 trial (US-based) in ALA is due to launch from mid-2024 and an announcement of expansion to new autoimmune indications is expected in 2024. Immix’s lead TSTx asset (IMX-110) is being investigated for the treatment of soft tissue sarcoma in Phase Ib/IIa studies; interim results have demonstrated positive safety and efficacy profiles. IMX-110 is also being assessed for the treatment of solid tumours in the Phase Ib/IIa IMMINENT-01 combination trial with tislelizumab; positive interim results have been reported in patients with colorectal cancer. We expect rolling data readouts for both NXC-201 and IMX-110 throughout 2024.
Y/E Dec | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 0.0 | (8.2) | (7.6) | (54.77) | N/A | N/A |
2023A | 0.0 | (16.1) | (13.0) | (75.14) | N/A | N/A |
2024E | 0.0 | (22.0) | (21.4) | (92.69) | N/A | N/A |
2025E | 0.0 | (26.0) | (26.5) | (100.68) | N/A | N/A |